Citadel Advisors’s MaxCyte MXCT Stock Holding History

Citadel Advisors’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-8,700	Closed	-$36.2K	–	15209
2024 Q4	$36.2K	Buy	8,700 +7,700	+770%	+$29.1K	﹤0.01%	12704
2024 Q3	$3.89K	Buy	1,000 +400	+67%	+$1.69K	﹤0.01%	13618
2024 Q2	$2.35K	Sell	600 -1,800	-75%	-$7.74K	﹤0.01%	13696
2024 Q1	$10.1K	Buy	+2,400	New	+$11.3K	﹤0.01%	13474
2023 Q4	–	Sell	-900	Closed	-$2.81K	–	14898
2023 Q3	$2.81K	Sell	900 -100	-10%	-$402	﹤0.01%	13670
2023 Q2	$4.59K	Sell	1,000 -1,900	-66%	-$8.73K	﹤0.01%	13585
2023 Q1	$14.4K	Sell	2,900 -600	-17%	-$2.96K	﹤0.01%	13316
2022 Q4	$19.1K	Sell	3,500 -8,900	-72%	-$54.6K	﹤0.01%	13186
2022 Q3	$81K	Buy	12,400 +200	+2%	+$1.12K	﹤0.01%	11274
2022 Q2	$58K	Buy	+12,200	New	+$60.1K	﹤0.01%	11842

Other funds holding MXCT

CFM

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BFM

Brooklands Fund Management London, United Kingdom $128M AUM

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Citadel Advisors's MXCT Position: Q2 2026 in Review

Citadel Advisors increased its MaxCyte (MXCT) stake by 157% in Q2 2026, buying an estimated $521K and bringing the position to 856,318 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #8074.

Citadel Advisors first reported a position in MXCT in Q4 2021 and has held it in 19 quarters since. The position peaked at $11.6M in Q4 2022. 123 funds tracked by Wall St. Rank hold MXCT as of Q2 2026.

Citadel Advisors held 856,318 shares of MaxCyte worth $1.05M as of Q2 2026.
Citadel Advisors bought 523,230 MaxCyte shares in Q2 2026, an estimated $521K.
MaxCyte made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #8074 holding.
Citadel Advisors first reported a position in MaxCyte in Q4 2021 and has held it in 19 quarters since.
Citadel Advisors's MaxCyte position peaked at $11.6M in Q4 2022.
123 funds tracked by Wall St. Rank held MaxCyte as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.